Gain Therapeutics, Inc.GANXNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank71
3Y CAGR+9.2%
5Y CAGR+29.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+9.2%/yr
vs +74.2%/yr prior
5Y CAGR
+29.1%/yr
Recent deceleration
Acceleration
-65.0pp
Decelerating
Percentile
P71
Within normal range
vs 5Y Ago
3.6x
Strong expansion
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $12.59M | -38.2% |
| 2024 | $20.35M | -8.8% |
| 2023 | $22.31M | +130.8% |
| 2022 | $9.67M | +42.2% |
| 2021 | $6.80M | +93.7% |
| 2020 | $3.51M | +63.8% |
| 2019 | $2.14M | +104.2% |
| 2018 | $1.05M | - |